ERBB2 (HER2) amplifications and co-occurring KRAS alterations in the circulating cell-free DNA of pancreatic ductal adenocarcinoma patients and response to HER2 inhibition

ERBB2 (HER2) amplifications and co-occurring KRAS alterations in the circulating cell-free DNA of pancreatic ductal adenocarcinoma patients and response to HER2 inhibition

PurposeDespite accumulating data regarding the genomic landscape of pancreatic ductal adenocarcinoma (PDAC), olaparib is the only biomarker-driven FDA-approved targeted therapy with a PDAC-specific approval. Treating ERBB2(HER2)-amplified PDAC with anti-HER2 therapy has been reported with mixed resu...

Full description

Bibliographic Details
Main Authors: Afsaneh Barzi, Caroline M. Weipert, Carin R. Espenschied, Victoria M. Raymond, Andrea Wang-Gillam, Mohammad Amin Nezami, Eva J. Gordon, Daruka Mahadevan, Kabir Mody
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-02-01
Series:Frontiers in Oncology
Subjects:
pancreatic cancer
HER2 amplification
ERBB2
ctDNA
liquid biopsy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1339302/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1339302/full

Similar Items